Aquinox (AQXP) Pharmaceuticals Stock Rises on Baker Brothers Stake

Shares of Aquinox Pharmaceuticals Inc. (AQXP) were trading up +3.44 or +19.93 percent in this morning’s premarket after news that Baker Brothers Advisors LP had purchased an additional amount of shares of the company after an offering the company made on September 10th. Aquinox Pharmaceutical shares closed at $17.26 per share, up +0.80 or +4.86 percent in Friday’s regular trading session.

Vancouver, British Columbia based Aqunox Pharmaceuticals began operations in 2006 as a spinoff from the BC Cancer Agency, the University of British Colombia and the Vancouver Coastal Health Research Institute.
The company is a clinical stage pharmaceutical company specializing in discovering and developing targeted therapies for inflammation and immuno- oncology. Its primary anti-inflammatory product candidates target SH2-containing inositol-5 phosphatase1 or SHIP1, a key regulator of a cellular signaling pathway in immune cells generally known as the P13K pathway. The company’s lead product candidate, AQX-1125 is a molecular activator of SHIP1, which can be taken orally. AQX-1125 has already successfully completed several preclinical studies and four Phase 2 clinical trials.

On September 9th, the company announced the pricing of an offering of 5,500,000 shares of its common stock to be sold to the public at a price of $15.50 per share. In addition to the offering, Aquinox granted the issue’s underwriters a 30-day option for the purchase of an additional 825,000 shares of common stock at the $15.50 public offering price. The offering is expected to close on September 15th, 2015.

In a filing with the Securities and Exchange Commission, dated September 12th, Aquinox disclosed that Baker Life Sciences, L.P. and 667 L.P. had purchased 2.21 million shares and 266,563 shares respectively at the company’s offering price of $15.50 per share on September 10th. The funds purchased a total of 2.48 million shares or almost half of the entire offering.

According to an amended 13D filing with the Securities and Exchange Commission, the funds run by Julian and Felix Baker have accumulated a 39.6 percent stake in the company. The ownership breakdown of the 17.05 million total shares outstanding for Aquinox disclosed to the SEC by the funds following the offering have 667, L.P. owning a 4.3 percent stake, while Baker Brothers Life Sciences, L.P. now owns 35.3 percent of the company’s outstanding stock.

Aquinox stock has been on a roller coaster since early August, when the company reported its lead product, AQX-1125 had met multiple secondary endpoints in a mid stage trial. The stock went from $1.79 per share and peaked at $55.75 per share in two days. A month earlier in July, the stock was hammered after a study showed no difference in results for the drug compared to a placebo.

Shareholders and the market have welcomed the news of the Baker brothers accumulation of Aquinox stock , sending the stock up almost 20 percent in this morning’s premarket. Nevertheless, the company is still showing a loss of -2.41 per share this year, whether the stock can continue higher or hold its gains will depend on AQX-1125 results in upcoming trials.

Other News About AQXP

Aquinox Has 33% Upside As These Four Catalysts Come Near

Canaccord Genuity analyst raises his price target for the stock from $10 to $22 per share.

Aquinox Improves Net Income with New Discoveries

R&D expenses for the company declined more than 20 percent in the second quarter reducing Aquinox’s liabilities and debt.

Other Stocks in the News

Solera agrees to $6.5 billion acquisition by Vista Equity affiliate

Vista Equity will pay $55.85 cash per share, a 53 percent premium over Solera’s Friday closing price.

Apple Says IPhone on Pace to Beat Last Year's First Weekend

Apple sold 10 million units in the first weekend in 2014.

Published on Sep 14, 2015
By Jay Hawk
Jay Hawk
Jay Hawk enjoyed a 12-year professional financial markets career incorporating extensive first hand futures and options experience obtained by trading in the stock, commodity and forex markets on U.S. exchanges. Since retiring as a full-time financial market professional, he has been actively trading stock, commodities, forex and options for his own account and managing funds for others, as well as writing financial market commentary and educational articles.

Copyrighted 2016. Content published with author's permission.

Posted in ...